Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacoepidemiology | 21 | 2024 | 350 | 4.870 |
Why?
|
Product Surveillance, Postmarketing | 20 | 2024 | 452 | 4.050 |
Why?
|
Angioedema | 8 | 2023 | 192 | 2.920 |
Why?
|
Confidentiality | 10 | 2023 | 609 | 2.920 |
Why?
|
Multicenter Studies as Topic | 9 | 2023 | 1722 | 2.740 |
Why?
|
United States Food and Drug Administration | 32 | 2024 | 1677 | 2.550 |
Why?
|
Databases, Factual | 42 | 2024 | 8035 | 2.010 |
Why?
|
Research Design | 20 | 2024 | 6180 | 2.000 |
Why?
|
Privacy | 6 | 2023 | 233 | 1.890 |
Why?
|
Comparative Effectiveness Research | 9 | 2018 | 718 | 1.780 |
Why?
|
Information Dissemination | 5 | 2020 | 1131 | 1.770 |
Why?
|
International Classification of Diseases | 15 | 2022 | 894 | 1.680 |
Why?
|
Propensity Score | 18 | 2024 | 1928 | 1.620 |
Why?
|
Computer Security | 5 | 2023 | 260 | 1.580 |
Why?
|
Adverse Drug Reaction Reporting Systems | 11 | 2024 | 488 | 1.500 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 8 | 2023 | 1523 | 1.440 |
Why?
|
Fluoroquinolones | 2 | 2023 | 308 | 1.400 |
Why?
|
Clinical Coding | 5 | 2021 | 181 | 1.400 |
Why?
|
Epidemiologic Research Design | 5 | 2019 | 368 | 1.390 |
Why?
|
Drug Prescriptions | 11 | 2020 | 1673 | 1.320 |
Why?
|
Sentinel Surveillance | 7 | 2024 | 293 | 1.190 |
Why?
|
Electronic Health Records | 24 | 2024 | 4775 | 1.150 |
Why?
|
Information Storage and Retrieval | 3 | 2022 | 822 | 1.120 |
Why?
|
Adamantane | 3 | 2017 | 169 | 1.120 |
Why?
|
Models, Statistical | 10 | 2024 | 5075 | 1.090 |
Why?
|
Gastrointestinal Hemorrhage | 6 | 2023 | 1131 | 1.070 |
Why?
|
Dipeptides | 3 | 2017 | 409 | 1.040 |
Why?
|
Algorithms | 20 | 2024 | 13981 | 1.040 |
Why?
|
Gastric Bypass | 8 | 2023 | 829 | 1.010 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2024 | 334 | 1.010 |
Why?
|
Drug Therapy | 2 | 2019 | 504 | 0.940 |
Why?
|
Data Collection | 7 | 2020 | 3315 | 0.930 |
Why?
|
Drug Utilization | 5 | 2018 | 1195 | 0.930 |
Why?
|
Bariatric Surgery | 8 | 2022 | 1005 | 0.900 |
Why?
|
Anti-Bacterial Agents | 13 | 2023 | 7408 | 0.880 |
Why?
|
Antidepressive Agents | 7 | 2024 | 2890 | 0.880 |
Why?
|
Medication Errors | 2 | 2019 | 784 | 0.860 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2018 | 1259 | 0.840 |
Why?
|
Hypoglycemic Agents | 11 | 2023 | 3150 | 0.810 |
Why?
|
Insurance | 1 | 2023 | 114 | 0.810 |
Why?
|
Choledocholithiasis | 1 | 2022 | 49 | 0.790 |
Why?
|
Cholecystitis, Acute | 1 | 2022 | 74 | 0.770 |
Why?
|
Pregnancy Complications | 8 | 2018 | 2942 | 0.760 |
Why?
|
United States | 69 | 2024 | 72461 | 0.760 |
Why?
|
Cholangitis | 1 | 2022 | 113 | 0.750 |
Why?
|
Warfarin | 7 | 2023 | 1518 | 0.750 |
Why?
|
Drug Labeling | 3 | 2019 | 251 | 0.740 |
Why?
|
Trazodone | 1 | 2020 | 68 | 0.730 |
Why?
|
Hydrochlorothiazide | 1 | 2021 | 94 | 0.730 |
Why?
|
Diabetes Mellitus, Type 2 | 13 | 2024 | 12293 | 0.720 |
Why?
|
Pharmaceutical Preparations | 6 | 2023 | 1091 | 0.710 |
Why?
|
Pregnancy Outcome | 8 | 2024 | 2907 | 0.700 |
Why?
|
Humans | 178 | 2024 | 760621 | 0.700 |
Why?
|
Antihypertensive Agents | 3 | 2021 | 2061 | 0.700 |
Why?
|
Poisson Distribution | 4 | 2019 | 507 | 0.700 |
Why?
|
Obesity, Morbid | 6 | 2022 | 1287 | 0.680 |
Why?
|
Proportional Hazards Models | 17 | 2023 | 12531 | 0.640 |
Why?
|
Incretins | 1 | 2019 | 103 | 0.640 |
Why?
|
Hypoglycemia | 2 | 2023 | 888 | 0.630 |
Why?
|
Mefenamic Acid | 1 | 2018 | 5 | 0.630 |
Why?
|
Cohort Studies | 36 | 2024 | 41335 | 0.620 |
Why?
|
Equipment and Supplies | 3 | 2020 | 275 | 0.610 |
Why?
|
Prescriptions | 5 | 2022 | 388 | 0.600 |
Why?
|
Computer Communication Networks | 4 | 2023 | 294 | 0.600 |
Why?
|
Diclofenac | 1 | 2018 | 67 | 0.590 |
Why?
|
Information Services | 1 | 2019 | 235 | 0.590 |
Why?
|
Naproxen | 1 | 2018 | 100 | 0.590 |
Why?
|
Morning Sickness | 1 | 2017 | 6 | 0.580 |
Why?
|
Self-Injurious Behavior | 1 | 2023 | 554 | 0.580 |
Why?
|
Drug Monitoring | 2 | 2014 | 965 | 0.580 |
Why?
|
National Health Programs | 1 | 2020 | 441 | 0.570 |
Why?
|
Statistics as Topic | 2 | 2014 | 2362 | 0.560 |
Why?
|
Niacin | 1 | 2017 | 119 | 0.550 |
Why?
|
Central Nervous System Stimulants | 3 | 2018 | 1174 | 0.550 |
Why?
|
Insurance Claim Review | 3 | 2020 | 738 | 0.540 |
Why?
|
Ibuprofen | 1 | 2018 | 229 | 0.540 |
Why?
|
Photosensitizing Agents | 1 | 2021 | 618 | 0.540 |
Why?
|
Influenza, Human | 4 | 2022 | 1528 | 0.540 |
Why?
|
Taiwan | 3 | 2023 | 505 | 0.540 |
Why?
|
Ondansetron | 1 | 2017 | 95 | 0.540 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 255 | 0.530 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2696 | 0.520 |
Why?
|
Aortic Aneurysm | 1 | 2020 | 648 | 0.520 |
Why?
|
Risk Adjustment | 1 | 2019 | 601 | 0.520 |
Why?
|
Prenatal Care | 3 | 2018 | 1129 | 0.510 |
Why?
|
Gastrectomy | 7 | 2023 | 679 | 0.510 |
Why?
|
Carcinoma, Basal Cell | 1 | 2021 | 559 | 0.500 |
Why?
|
Antiemetics | 1 | 2017 | 187 | 0.500 |
Why?
|
Pregnancy | 33 | 2024 | 29749 | 0.490 |
Why?
|
Health Care Surveys | 4 | 2016 | 2435 | 0.490 |
Why?
|
Drug Approval | 7 | 2021 | 816 | 0.480 |
Why?
|
Female | 93 | 2024 | 391270 | 0.470 |
Why?
|
Pregnancy Trimester, First | 4 | 2022 | 908 | 0.470 |
Why?
|
Myocardial Infarction | 8 | 2022 | 11891 | 0.460 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2282 | 0.460 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2018 | 321 | 0.460 |
Why?
|
Computer Simulation | 11 | 2024 | 6218 | 0.450 |
Why?
|
Software | 4 | 2017 | 4419 | 0.450 |
Why?
|
Cardiovascular System | 2 | 2019 | 850 | 0.450 |
Why?
|
Population Surveillance | 5 | 2018 | 2608 | 0.450 |
Why?
|
Pregnancy Trimesters | 4 | 2018 | 197 | 0.450 |
Why?
|
Meta-Analysis as Topic | 2 | 2015 | 1376 | 0.440 |
Why?
|
Antiviral Agents | 6 | 2022 | 3061 | 0.440 |
Why?
|
Aortic Valve | 1 | 2023 | 1996 | 0.440 |
Why?
|
Estrogen Replacement Therapy | 2 | 2010 | 1206 | 0.440 |
Why?
|
Bupropion | 2 | 2024 | 304 | 0.430 |
Why?
|
Hypolipidemic Agents | 1 | 2017 | 626 | 0.420 |
Why?
|
Adult | 61 | 2024 | 219994 | 0.420 |
Why?
|
Intracranial Hemorrhages | 2 | 2018 | 844 | 0.420 |
Why?
|
Hyperlipidemias | 1 | 2017 | 782 | 0.410 |
Why?
|
Research Personnel | 1 | 2017 | 582 | 0.410 |
Why?
|
Pancreatitis | 1 | 2019 | 1100 | 0.410 |
Why?
|
Medroxyprogesterone Acetate | 2 | 2010 | 155 | 0.410 |
Why?
|
Selection Bias | 4 | 2022 | 358 | 0.400 |
Why?
|
Angiotensin Receptor Antagonists | 3 | 2013 | 1031 | 0.400 |
Why?
|
Middle Aged | 58 | 2024 | 220352 | 0.400 |
Why?
|
Glyburide | 3 | 2023 | 114 | 0.400 |
Why?
|
Anti-Asthmatic Agents | 4 | 2020 | 565 | 0.400 |
Why?
|
Probability | 6 | 2023 | 2475 | 0.400 |
Why?
|
Antirheumatic Agents | 3 | 2019 | 1374 | 0.390 |
Why?
|
Regression Analysis | 4 | 2019 | 6360 | 0.390 |
Why?
|
Incidence | 13 | 2024 | 21392 | 0.390 |
Why?
|
Medical Informatics Applications | 1 | 2013 | 178 | 0.380 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2018 | 3701 | 0.380 |
Why?
|
Young Adult | 36 | 2022 | 58741 | 0.380 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2013 | 297 | 0.380 |
Why?
|
Oseltamivir | 3 | 2022 | 76 | 0.380 |
Why?
|
Nicotinic Agonists | 1 | 2013 | 265 | 0.370 |
Why?
|
Quinoxalines | 1 | 2013 | 297 | 0.370 |
Why?
|
Benzazepines | 1 | 2013 | 311 | 0.370 |
Why?
|
Clindamycin | 2 | 2023 | 140 | 0.370 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2290 | 0.360 |
Why?
|
Anticoagulants | 5 | 2020 | 4897 | 0.360 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2024 | 4357 | 0.360 |
Why?
|
Outpatients | 1 | 2018 | 1607 | 0.350 |
Why?
|
Dementia | 3 | 2023 | 2649 | 0.350 |
Why?
|
Perinatal Care | 2 | 2013 | 242 | 0.340 |
Why?
|
Pregnancy, Unplanned | 1 | 2010 | 88 | 0.340 |
Why?
|
Stroke | 7 | 2023 | 9962 | 0.340 |
Why?
|
Odds Ratio | 3 | 2019 | 9716 | 0.340 |
Why?
|
Heart Failure | 3 | 2019 | 11847 | 0.340 |
Why?
|
Adolescent | 33 | 2022 | 87810 | 0.330 |
Why?
|
Retrospective Studies | 36 | 2024 | 80372 | 0.320 |
Why?
|
Live Birth | 4 | 2022 | 512 | 0.320 |
Why?
|
Aged | 34 | 2024 | 169152 | 0.310 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 275 | 0.310 |
Why?
|
Male | 55 | 2024 | 359744 | 0.310 |
Why?
|
Brain Ischemia | 1 | 2022 | 3127 | 0.310 |
Why?
|
Contraceptives, Oral | 1 | 2010 | 554 | 0.300 |
Why?
|
Renin-Angiotensin System | 1 | 2012 | 738 | 0.300 |
Why?
|
Atrial Fibrillation | 5 | 2022 | 5209 | 0.300 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3334 | 0.300 |
Why?
|
Drug Utilization Review | 3 | 2018 | 251 | 0.300 |
Why?
|
Gestational Age | 3 | 2022 | 3565 | 0.290 |
Why?
|
Biostatistics | 1 | 2008 | 164 | 0.280 |
Why?
|
Cardiomyopathies | 1 | 2018 | 1952 | 0.270 |
Why?
|
Delivery of Health Care | 6 | 2024 | 5325 | 0.270 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 3201 | 0.270 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2019 | 2496 | 0.270 |
Why?
|
Hospitalization | 9 | 2024 | 10790 | 0.270 |
Why?
|
Ambulatory Care | 2 | 2016 | 2781 | 0.270 |
Why?
|
Risk Factors | 19 | 2024 | 74359 | 0.260 |
Why?
|
Prevalence | 11 | 2021 | 15687 | 0.260 |
Why?
|
Birth Certificates | 4 | 2013 | 70 | 0.260 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 2 | 2017 | 108 | 0.260 |
Why?
|
Antipsychotic Agents | 3 | 2019 | 3061 | 0.260 |
Why?
|
Anticonvulsants | 3 | 2022 | 1879 | 0.260 |
Why?
|
Fetal Growth Retardation | 1 | 2009 | 579 | 0.260 |
Why?
|
Delivery, Obstetric | 1 | 2013 | 932 | 0.250 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4024 | 0.250 |
Why?
|
Sulfonylurea Compounds | 2 | 2017 | 221 | 0.250 |
Why?
|
Body Height | 2 | 2022 | 1570 | 0.250 |
Why?
|
Suicide | 2 | 2018 | 1599 | 0.250 |
Why?
|
Insulin, Long-Acting | 2 | 2017 | 58 | 0.240 |
Why?
|
Infant, Newborn | 14 | 2021 | 26181 | 0.230 |
Why?
|
Depressive Disorder | 2 | 2019 | 3726 | 0.230 |
Why?
|
Sulbactam | 1 | 2023 | 31 | 0.230 |
Why?
|
Logistic Models | 6 | 2020 | 13314 | 0.230 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2023 | 33 | 0.230 |
Why?
|
Follow-Up Studies | 11 | 2020 | 39261 | 0.220 |
Why?
|
Thiazolidinediones | 2 | 2017 | 465 | 0.220 |
Why?
|
Medicare | 3 | 2024 | 6786 | 0.220 |
Why?
|
Ampicillin | 1 | 2023 | 141 | 0.220 |
Why?
|
Body Mass Index | 8 | 2021 | 12914 | 0.220 |
Why?
|
Fertilization | 2 | 2019 | 197 | 0.220 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3865 | 0.220 |
Why?
|
Medical Record Linkage | 4 | 2023 | 288 | 0.210 |
Why?
|
Mood Disorders | 1 | 2009 | 1124 | 0.210 |
Why?
|
Consumer Product Safety | 2 | 2014 | 123 | 0.210 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2009 | 518 | 0.210 |
Why?
|
Cephalosporins | 1 | 2023 | 204 | 0.210 |
Why?
|
Fumarates | 2 | 2013 | 131 | 0.210 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15757 | 0.200 |
Why?
|
Neoplasms | 4 | 2021 | 22072 | 0.200 |
Why?
|
Causality | 3 | 2024 | 1242 | 0.200 |
Why?
|
Dementia, Vascular | 1 | 2023 | 123 | 0.200 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58995 | 0.190 |
Why?
|
Medication Adherence | 2 | 2010 | 2165 | 0.190 |
Why?
|
Time Factors | 13 | 2020 | 40165 | 0.190 |
Why?
|
Drug Interactions | 2 | 2020 | 1428 | 0.190 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5799 | 0.190 |
Why?
|
Smoking Cessation | 1 | 2013 | 2064 | 0.190 |
Why?
|
Insurance, Medigap | 1 | 2020 | 21 | 0.190 |
Why?
|
Postmenopause | 1 | 2010 | 2509 | 0.180 |
Why?
|
Feasibility Studies | 3 | 2022 | 5201 | 0.180 |
Why?
|
Endpoint Determination | 2 | 2014 | 597 | 0.180 |
Why?
|
Amides | 2 | 2013 | 448 | 0.180 |
Why?
|
Peptic Ulcer | 1 | 2022 | 219 | 0.180 |
Why?
|
Anti-Infective Agents | 1 | 2008 | 981 | 0.180 |
Why?
|
Mothers | 2 | 2022 | 2186 | 0.180 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 26 | 0.170 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 30 | 0.170 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4541 | 0.170 |
Why?
|
Medical Records | 5 | 2020 | 1407 | 0.170 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12159 | 0.170 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9185 | 0.170 |
Why?
|
Child, Preschool | 13 | 2022 | 42063 | 0.170 |
Why?
|
Case-Control Studies | 4 | 2020 | 22053 | 0.170 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 2250 | 0.170 |
Why?
|
Orphan Drug Production | 1 | 2020 | 48 | 0.170 |
Why?
|
Brain Infarction | 2 | 2018 | 292 | 0.160 |
Why?
|
Body Weight | 2 | 2021 | 4611 | 0.160 |
Why?
|
Pain, Intractable | 1 | 2020 | 132 | 0.160 |
Why?
|
Government Regulation | 2 | 2014 | 525 | 0.160 |
Why?
|
Zanamivir | 1 | 2018 | 21 | 0.160 |
Why?
|
Reference Standards | 1 | 2022 | 1004 | 0.160 |
Why?
|
Stillbirth | 1 | 2022 | 368 | 0.160 |
Why?
|
Risk Assessment | 10 | 2020 | 24123 | 0.160 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3763 | 0.150 |
Why?
|
Acute Disease | 3 | 2018 | 7269 | 0.150 |
Why?
|
Neural Tube Defects | 1 | 2020 | 254 | 0.150 |
Why?
|
Canada | 2 | 2023 | 2128 | 0.150 |
Why?
|
Pregnancy in Diabetics | 1 | 2019 | 194 | 0.150 |
Why?
|
Asthma | 4 | 2020 | 6172 | 0.150 |
Why?
|
Age Factors | 4 | 2021 | 18416 | 0.150 |
Why?
|
Diabetes, Gestational | 3 | 2019 | 1242 | 0.150 |
Why?
|
Health Benefit Plans, Employee | 1 | 2020 | 333 | 0.150 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 116 | 0.150 |
Why?
|
Glipizide | 1 | 2017 | 48 | 0.150 |
Why?
|
Schizophrenia | 3 | 2019 | 6915 | 0.150 |
Why?
|
Off-Label Use | 1 | 2019 | 184 | 0.150 |
Why?
|
Registries | 3 | 2018 | 8469 | 0.150 |
Why?
|
Premature Birth | 1 | 2009 | 1771 | 0.150 |
Why?
|
Spondylitis, Ankylosing | 1 | 2018 | 152 | 0.140 |
Why?
|
Fenofibrate | 1 | 2017 | 88 | 0.140 |
Why?
|
Gastroplasty | 2 | 2018 | 157 | 0.140 |
Why?
|
Infant | 10 | 2022 | 36060 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1594 | 0.140 |
Why?
|
Child | 17 | 2022 | 79806 | 0.140 |
Why?
|
Weight Gain | 2 | 2024 | 2347 | 0.140 |
Why?
|
Metformin | 2 | 2022 | 912 | 0.140 |
Why?
|
Electronics | 3 | 2022 | 315 | 0.130 |
Why?
|
Reproducibility of Results | 7 | 2024 | 20080 | 0.130 |
Why?
|
Trimethoprim | 1 | 2015 | 84 | 0.130 |
Why?
|
Suicidal Ideation | 2 | 2023 | 1425 | 0.130 |
Why?
|
Ultraviolet Rays | 1 | 2021 | 1078 | 0.130 |
Why?
|
Legislation, Drug | 1 | 2018 | 214 | 0.130 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 219 | 0.130 |
Why?
|
Piperidines | 1 | 2024 | 1650 | 0.130 |
Why?
|
Pilot Projects | 6 | 2021 | 8555 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1869 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 5990 | 0.120 |
Why?
|
Quinolines | 1 | 2020 | 759 | 0.120 |
Why?
|
Treatment Outcome | 11 | 2024 | 65017 | 0.120 |
Why?
|
Fractures, Bone | 1 | 2007 | 2041 | 0.120 |
Why?
|
Aromatase Inhibitors | 1 | 2019 | 511 | 0.120 |
Why?
|
Antithrombins | 1 | 2017 | 313 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2019 | 2125 | 0.120 |
Why?
|
Pregnancy, Multiple | 2 | 2013 | 215 | 0.120 |
Why?
|
Rare Diseases | 1 | 2020 | 619 | 0.120 |
Why?
|
Weight Loss | 3 | 2022 | 2686 | 0.120 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 961 | 0.110 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2013 | 36 | 0.110 |
Why?
|
Research Subjects | 1 | 2015 | 249 | 0.110 |
Why?
|
Patient Compliance | 2 | 2018 | 2688 | 0.110 |
Why?
|
Drug Costs | 1 | 2021 | 1185 | 0.110 |
Why?
|
Epidemiologic Methods | 2 | 2015 | 1343 | 0.110 |
Why?
|
Linear Models | 2 | 2022 | 5877 | 0.110 |
Why?
|
Labor, Induced | 1 | 2014 | 151 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 533 | 0.110 |
Why?
|
Opioid-Related Disorders | 2 | 2021 | 2138 | 0.110 |
Why?
|
Patient Readmission | 2 | 2017 | 3323 | 0.110 |
Why?
|
Hemorrhage | 3 | 2020 | 3600 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 496 | 0.110 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2015 | 338 | 0.100 |
Why?
|
Insulin | 4 | 2023 | 6597 | 0.100 |
Why?
|
Disease | 1 | 2017 | 671 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2008 | 14495 | 0.100 |
Why?
|
Depressive Disorder, Major | 3 | 2019 | 4744 | 0.100 |
Why?
|
Sex Factors | 3 | 2021 | 10547 | 0.100 |
Why?
|
Health Policy | 3 | 2021 | 2677 | 0.100 |
Why?
|
Colitis, Ulcerative | 1 | 2024 | 1919 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3016 | 0.100 |
Why?
|
Predictive Value of Tests | 8 | 2020 | 15289 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1677 | 0.100 |
Why?
|
Alzheimer Disease | 2 | 2023 | 8547 | 0.100 |
Why?
|
Demography | 2 | 2023 | 1650 | 0.090 |
Why?
|
Anaphylaxis | 1 | 2018 | 755 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2018 | 557 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2017 | 1817 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 10344 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1195 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2019 | 1572 | 0.090 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5889 | 0.090 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1257 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2131 | 0.090 |
Why?
|
Goals | 1 | 2015 | 708 | 0.090 |
Why?
|
Glucose | 1 | 2022 | 4351 | 0.090 |
Why?
|
Crohn Disease | 1 | 2022 | 2275 | 0.090 |
Why?
|
Medical Records Systems, Computerized | 2 | 2013 | 1191 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 384 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2024 | 2421 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 585 | 0.080 |
Why?
|
Pre-Eclampsia | 2 | 2009 | 1229 | 0.080 |
Why?
|
Overweight | 1 | 2020 | 2421 | 0.080 |
Why?
|
Suicide, Attempted | 1 | 2018 | 1378 | 0.080 |
Why?
|
Comorbidity | 3 | 2018 | 10551 | 0.080 |
Why?
|
Prescription Drugs | 1 | 2016 | 630 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2013 | 699 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 10827 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3455 | 0.080 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 2176 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2018 | 21025 | 0.080 |
Why?
|
Hypertension | 2 | 2018 | 8594 | 0.070 |
Why?
|
Random Allocation | 2 | 2011 | 2394 | 0.070 |
Why?
|
California | 1 | 2012 | 1416 | 0.070 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 796 | 0.070 |
Why?
|
Patient-Centered Care | 3 | 2023 | 1416 | 0.070 |
Why?
|
Tobacco Use Disorder | 1 | 2013 | 700 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2916 | 0.070 |
Why?
|
Risk | 3 | 2018 | 9631 | 0.070 |
Why?
|
Advisory Committees | 1 | 2011 | 788 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1895 | 0.070 |
Why?
|
Laparoscopy | 2 | 2018 | 2147 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 1348 | 0.070 |
Why?
|
Maternal Exposure | 1 | 2013 | 1045 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2365 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6498 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2010 | 12427 | 0.060 |
Why?
|
Sulfonamides | 1 | 2015 | 1977 | 0.060 |
Why?
|
Chronic Disease | 2 | 2018 | 9287 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1864 | 0.060 |
Why?
|
Program Development | 1 | 2012 | 1297 | 0.060 |
Why?
|
Prospective Studies | 6 | 2023 | 54303 | 0.060 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2332 | 0.060 |
Why?
|
Women's Health | 1 | 2014 | 2056 | 0.060 |
Why?
|
Liver Diseases | 1 | 2013 | 1302 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2932 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2061 | 0.060 |
Why?
|
Postoperative Complications | 4 | 2020 | 15697 | 0.060 |
Why?
|
Treatment Failure | 1 | 2010 | 2648 | 0.060 |
Why?
|
Genetic Testing | 1 | 2017 | 3531 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2013 | 1380 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2283 | 0.060 |
Why?
|
Estrogens | 1 | 2010 | 1520 | 0.050 |
Why?
|
Fetal Development | 1 | 2009 | 766 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3763 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2014 | 1939 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13262 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2012 | 1588 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3224 | 0.050 |
Why?
|
Administration, Oral | 2 | 2021 | 4035 | 0.050 |
Why?
|
Laxatives | 1 | 2023 | 90 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7806 | 0.050 |
Why?
|
Models, Structural | 1 | 2022 | 341 | 0.050 |
Why?
|
Biomedical Research | 2 | 2020 | 3426 | 0.050 |
Why?
|
Maternal Age | 2 | 2016 | 807 | 0.050 |
Why?
|
Genomics | 1 | 2017 | 5794 | 0.050 |
Why?
|
Citalopram | 1 | 2024 | 402 | 0.050 |
Why?
|
Carbamazepine | 1 | 2022 | 224 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2003 | 0.050 |
Why?
|
Oxymorphone | 1 | 2020 | 6 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14660 | 0.040 |
Why?
|
Levonorgestrel | 1 | 2020 | 74 | 0.040 |
Why?
|
Filgrastim | 1 | 2019 | 132 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5697 | 0.040 |
Why?
|
Insurance, Health | 1 | 2012 | 2501 | 0.040 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 136 | 0.040 |
Why?
|
Sulfides | 1 | 2020 | 171 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6544 | 0.040 |
Why?
|
Hematologic Agents | 1 | 2019 | 41 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2010 | 6828 | 0.040 |
Why?
|
Valproic Acid | 1 | 2022 | 441 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 431 | 0.040 |
Why?
|
Acetates | 1 | 2020 | 321 | 0.040 |
Why?
|
Pain | 1 | 2014 | 5066 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2013 | 3959 | 0.040 |
Why?
|
Oxycodone | 1 | 2020 | 138 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13630 | 0.040 |
Why?
|
Decision Making | 3 | 2020 | 3925 | 0.040 |
Why?
|
Insemination, Artificial | 1 | 2019 | 99 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1612 | 0.040 |
Why?
|
Constipation | 1 | 2023 | 561 | 0.040 |
Why?
|
Capital Financing | 1 | 2017 | 59 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2023 | 783 | 0.040 |
Why?
|
Fertility | 1 | 2022 | 773 | 0.040 |
Why?
|
Epilepsy | 1 | 2012 | 3267 | 0.040 |
Why?
|
Health Status | 1 | 2009 | 4081 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2024 | 1135 | 0.030 |
Why?
|
Recurrence | 2 | 2022 | 8482 | 0.030 |
Why?
|
Drug and Narcotic Control | 1 | 2015 | 145 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 844 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2017 | 1156 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25942 | 0.030 |
Why?
|
HIV Infections | 1 | 2020 | 17165 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2024 | 2622 | 0.030 |
Why?
|
Blood Pressure | 1 | 2009 | 8525 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1579 | 0.030 |
Why?
|
Risk-Taking | 1 | 2018 | 998 | 0.030 |
Why?
|
Obstetric Labor Complications | 1 | 2014 | 236 | 0.030 |
Why?
|
Drug Combinations | 1 | 2017 | 2025 | 0.020 |
Why?
|
Postpartum Period | 1 | 2018 | 1167 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2019 | 1292 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4899 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2013 | 582 | 0.020 |
Why?
|
Pregnancy Trimester, Second | 1 | 2013 | 732 | 0.020 |
Why?
|
Oxygen | 1 | 2021 | 4193 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1575 | 0.020 |
Why?
|
Epidemiology | 1 | 2011 | 278 | 0.020 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2013 | 377 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2017 | 2145 | 0.020 |
Why?
|
Data Mining | 1 | 2013 | 553 | 0.020 |
Why?
|
Medicaid | 1 | 2021 | 2815 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15840 | 0.020 |
Why?
|
Infertility, Female | 1 | 2013 | 759 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3465 | 0.020 |
Why?
|
Specialization | 1 | 2011 | 778 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2622 | 0.020 |
Why?
|
Sweden | 1 | 2009 | 1381 | 0.020 |
Why?
|
Parity | 1 | 2009 | 925 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 936 | 0.020 |
Why?
|
Health Services Research | 1 | 2013 | 1810 | 0.020 |
Why?
|
Gynecology | 1 | 2011 | 528 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1500 | 0.020 |
Why?
|
Obstetrics | 1 | 2011 | 667 | 0.010 |
Why?
|
Obesity | 2 | 2020 | 12922 | 0.010 |
Why?
|
Patient Discharge | 1 | 2017 | 3476 | 0.010 |
Why?
|
Program Evaluation | 1 | 2012 | 2493 | 0.010 |
Why?
|
Biological Products | 1 | 2012 | 916 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8044 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8624 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12808 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3836 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7818 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7475 | 0.010 |
Why?
|
Animals | 1 | 2007 | 167963 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5351 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 11345 | 0.000 |
Why?
|